REG - Oxford Biomedica PLC Prudential PLC - Holding(s) in Company <Origin Href="QuoteRef">OXB.L</Origin> <Origin Href="QuoteRef">PRU.L</Origin>

Oxford BioMedicaAnnouncement

01/03/2016 09:50

RNS Number : 6097Q
Oxford Biomedica PLC
01 March 2016
For filings with the FCA include the annex

For filings with issuer exclude the annex


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi


1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:ii
Oxford Biomedica Plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
x
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify): 


3. Full name of person(s) subject to the
notification obligation:iii
Prudential plc group of companies
4. Full name of shareholder(s)
(if different from 3.):iv
Prudential plc
M&G Group Limited
M&G Limited
M&G Investment Management Limited
M&G Securities Limited
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
25 February 2016
6. Date on which issuer notified:
29 February 2016
7. Threshold(s) that is/are crossed or
reached: vi, vii
17% -18%


8. Notified details:
A: Voting rights attached to sharesviii, ix
Class/type of
shares

if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
ORD GBP0.01
GB0006648157
460,648,423
460,648,423
490,443,106
0
490,443,106
0
18.14%

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights






C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx




Nominal
Delta



Total (A+B+C)
Number of voting rights
Percentage of voting rights
490,443,106
18.14%
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
Prudential plc (parent Company) - 490,443,106 (18.14%)
M&G Group Limited (wholly owned subsidiary of Prudential plc) - 490,443,106 (18.14%)
M&G Limited (wholly owned subsidiary of M&G Group Limited) - 490,443,106 (18.14%)
M&G Investment Management Limited (wholly owned subsidiary of M&G Limited) - 490,443,106 (18.14%)
M&G Securities Limited (wholly owned subsidiary of M&G Limited) - 466,658,885 (17.26%)

Proxy Voting:
10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will ceaseto hold:
N/A
12. Date on which proxy holder will cease to holdvoting rights:
N/A


13. Additional information:
14. Contact name:
Tim Watts
15. Contact telephone number:
Chief Financial Officer, Oxford BioMedica

This information is provided by RNS
The company news service from the London Stock Exchange
  END
HOLUASKRNVAORRR